Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the company, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have covered the stock in the last year is $90.63.
KROS has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Oppenheimer initiated coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 target price on the stock. Guggenheim assumed coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. Truist Financial reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Bank of America reduced their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th.
Read Our Latest Stock Analysis on Keros Therapeutics
Insiders Place Their Bets
Institutional Trading of Keros Therapeutics
Several large investors have recently added to or reduced their stakes in the stock. Rafferty Asset Management LLC boosted its position in shares of Keros Therapeutics by 12.2% during the 4th quarter. Rafferty Asset Management LLC now owns 65,281 shares of the company’s stock valued at $2,596,000 after acquiring an additional 7,092 shares during the last quarter. Platinum Investment Management Ltd. acquired a new position in Keros Therapeutics in the 4th quarter valued at about $1,944,000. Superstring Capital Management LP purchased a new stake in shares of Keros Therapeutics in the 4th quarter valued at approximately $2,968,000. ADAR1 Capital Management LLC acquired a new stake in shares of Keros Therapeutics during the 4th quarter worth approximately $27,367,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Keros Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 360,467 shares of the company’s stock valued at $14,332,000 after buying an additional 61,992 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.
Keros Therapeutics Stock Performance
KROS opened at $59.90 on Friday. The company has a fifty day moving average of $50.94 and a two-hundred day moving average of $52.55. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -11.63 and a beta of 1.23. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The business had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period in the previous year, the company posted ($1.27) EPS. On average, equities research analysts forecast that Keros Therapeutics will post -4.88 earnings per share for the current year.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Stories
- Five stocks we like better than Keros Therapeutics
- How to Use the MarketBeat Dividend Calculator
- When Is the Best Time to Invest in Mutual Funds?
- Stock Average Calculator
- Is NVIDIA Stock in a Correction or Consolidation?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.